Journal of Clinical Oncology, Vol 15, 1965-1973, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose- limiting

AN Gordon, CA Stringer, CM Matthews, DL Willis and J Nemunaitis
Division of Gynecology, Physician Reliance Network, Inc, Dallas, TX, USA.

PURPOSE: To determine the maximum-tolerable dose (MTD) of paclitaxel in a phase I dose-escalation study when combined with cisplatin in patients with advanced ovarian cancer receiving filgrastim for prophylaxis of myelosuppression. PATIENTS AND METHODS: A total of 23 patients with stage II (bulky residual), III, or IV epithelial ovarian cancer were treated (following debulking surgery) with paclitaxel as a 3-hour infusion followed by cisplatin (75 mg/m2) administered over 4 hours on day 1, repeated every 21 days for six cycles. Filgrastim (5 micrograms/kg/d) was administered subcutaneously (SC) beginning on day 2 of each cycle through neutrophil recovery (absolute neutrophil count [ANC] > 10,000/microL). Patients were assigned to one of six escalating dose levels of paclitaxel: 150 (n = 3), 175 (n = 3), 200 (n = 3), 225 (n = 4), 250 (n = 4), and 275 mg/m2 (n = 6). RESULTS: At each paclitaxel dose level (150, 175, 200, 225, 250, and 275 mg/m2), the numbers of patients who completed six cycles without dose reduction were three (100%), three (100%), two (66%), two (50%), three (75%), and zero (0%), respectively. The numbers of patients who experienced a grade III/IV adverse event (hematologic or nonhematologic) were zero (0%), two (66%), two (66%), one (25%), four (100%), and five (80%), respectively. Reasons for dose reduction included neurotoxicity (225 mg/m2, n = 1; 275 mg/m2, n = 2), neutropenia (225 mg/m2, n = 2), diarrhea (275 mg/m2, n = 2), and nephrotoxicity (225 mg/m2, n = 1). Reasons for not completing six cycles at full or reduced dose included neuropathy (200, 225, and 275 mg/m2, n = 1 each) physician request (275 mg/m2, n = 1), and death (275 mg/m2, n = 1). Hematopoietic toxicity was minimal. Six patients developed grade III/IV neutropenia. No patient developed thrombocytopenia below a level of 50,000/microL. CONCLUSION: The MTD of paclitaxel was determined to be 225 mg/m2 when administered as a 3-hour infusion and combined with cisplatin (75 mg/m2). Nonhematologic dose-limiting toxicities were neuropathy and diarrhea. The neuropathy often had a rapid onset, especially at the higher dose levels.

This article has been cited by other articles:

				D. K. Armstrong, D. Spriggs, J. Levin, R. Poulin, and S. Lane Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis Oncologist, October 1, 2005; 10(9): 686 - 694. [Abstract] [Full Text] [PDF]

				C. J. Dunton Management of Treatment-Related Toxicity in Advanced Ovarian Cancer Oncologist, October 1, 2002; 7(90005): 11 - 19. [Abstract] [Full Text] [PDF]

				M. Hidalgo, C. Aylesworth, L. A. Hammond, C. D. Britten, G. Weiss, J. Stephenson Jr, G. Schwartz, A. Patnaik, L. Smith, K. Molpus, et al. Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel J. Clin. Oncol., May 1, 2001; 19(9): 2493 - 2503. [Abstract] [Full Text] [PDF]

				M. H. Cohen, S. Hirschfeld, S. F. Honig, A. Ibrahim, J. R. Johnson, J. J. O'Leary, R. M. White, G. A. Williams, and R. Pazdur Drug Approval Summaries: Arsenic Trioxide, Tamoxifen Citrate, Anastrazole, Paclitaxel, Bexarotene Oncologist, February 1, 2001; 6(1): 4 - 11. [Abstract] [Full Text]